1. |
Doll R, Hill AB. Smoking and Carcinoma of the Lung; preliminary report. Br Med J, 1950, 2 : 739-748.
|
2. |
Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol, 2007, 25: 472 -478.
|
3. |
景霞, 許建英. 吸煙對大鼠氣道上皮細胞基質金屬蛋白酶9 表達的影響. 中國呼吸與危重監護雜志, 2009, 8: 220-223.
|
4. |
Sardari Nia P, Weyler J, Colpaert C, et al. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer,2005, 47: 351 -359.
|
5. |
Shriver SP, Bourdeau HA, Gubish CT, et al. Sex-specific expression of gastrin-realing peptide receptor-relationship to smoking history and risk of lung cancer. J Natl Cancer Inst, 2000 , 92: 24-33.
|
6. |
Van Rens MT, de la Rivière AB, Elbers HR, et al. Prognostic assessment of 2 , 361 patients who underwent pulmonary resection for non-small cell lung cancer, Stage I, II, and IIIA. Chest, 2000, 117 :374-379.
|
7. |
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-smallcell lung cancer: results from a randomized, placebo-controlled,multicentre study ( Iressa Survival Evaluation in Lung Cancer ) .Lancet, 2005 , 366: 1527 -1537 .
|
8. |
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005 ,353: 123-132 .
|